What changed from existing technology?
This study tested a plant extract and a gold nanoparticle version of it against cancer cells, finding they killed the cancer cells more effectively than normal cells.
This is the first study to demonstrate the enhanced cytotoxicity of D. meyeniana extract when combined with gold nanoparticles, showing selective killing of cancer cells.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
nticancer potential, although experimental validation remains limited. This study evaluated the cytotoxic and molecular effects of D. meyeniana extract (
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest potential for further development of D. meyeniana extract and its gold nanoparticle formulation as targeted cancer therapies, though clinical validation is needed.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.